Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.
Odette S ReifsniderAli TafazzoliStephan LindenJack IshakPal RakonczaiMatthew StargardterEffie KutiPublished in: Journal of the American Heart Association (2024)
Empagliflozin plus standard of care may prevent hospitalizations for heart failure, extend life, and increase quality-adjusted life years for patients with heart failure with reduced ejection fraction at an acceptable cost for US payors.